Loading
PSMA PET-CT was 27 percentage points more accurate than CT and bone scan for finding spread in men with high-risk prostate cancer before treatment, with less radiation and more influence on management, and it has replaced conventional imaging where available.
Randomised multicentre trial of 302 men with high-risk localised prostate cancer randomised to conventional imaging (CT and bone scan) or gallium-68 PSMA PET-CT for staging, with crossover imaging to define a reference standard.
Accuracy was 92 percent for PSMA PET-CT against 65 percent for conventional imaging, with higher sensitivity (85 versus 38 percent) and specificity, fewer equivocal results, lower radiation dose and more frequent management change.
PSMA PET-CT is the preferred staging investigation for high-risk prostate cancer and for biochemical recurrence, though most treatment trials were designed with conventional imaging.
Shares PSMA expression by PET (PSMA-positive), Theranostics, Prostate cancer (KEGG map), PSMA.
Shares PSMA expression by PET (PSMA-positive), Theranostics, Prostate cancer (KEGG map), PSMA.
Shares PSMA expression by PET (PSMA-positive), Theranostics, PSMA, PSMA PET.
Shares PSMA expression by PET (PSMA-positive), Theranostics, PSMA, PSMA PET.
Shares proPSMA, PSMA, PSMA PET, Prostate cancer.
Shares PSMA expression by PET (PSMA-positive), Theranostics, PSMA, PSMA PET.
Shares proPSMA, PSMA, PSMA PET, Prostate cancer.
Shares PSMA, Localised prostate cancer, high and very high risk, PSMA PET, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/